multitarget anticancer agent (MultiTarget Pharmaceuticals)
90
Structured Review
MultiTarget Pharmaceuticals
multitarget anticancer agent
Multitarget Anticancer Agent, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget+anticancer+agent/anticancer+copper+ii++multitarget+pro+drug/pmc11585289-159-9-9
Average 90 stars, based on 1 article reviews
Multitarget Anticancer Agent, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget+anticancer+agent/anticancer+copper+ii++multitarget+pro+drug/pmc11585289-159-9-9
Average 90 stars, based on 1 article reviews
multitarget anticancer agent - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "The role of andrographolide as a potential anticancer agent against gastric cancer cell lines: a systematic review"
Article Title: The role of andrographolide as a potential anticancer agent against gastric cancer cell lines: a systematic review
Journal: PeerJ
doi: 10.7717/peerj.18513
Figure Legend Snippet: PICO element for inclusion and exclusion criteria.
Techniques Used: Comparison, Activity Assay
Figure Legend Snippet: Schematic representation of the principal gastric cancer cell lines tested to determine the anticancer effects of andrographolide.
Techniques Used:
Related Articles
Activity Assay:Article Title: Thalidomide: History of Research and Perspectives for Its Medical Use (Review) Article Snippet: Thalidomide was used in the 1950s as a sedative.. As a result of its marked teratogenicity, it was removed from the market in the 1960s, but returned to the clinic some 40 years later as an antitumor agent.. Thalidomide and its derivatives (IMiD and CELMoD) are currently in active use in the treatment of a number of hematological tumors. other:Article Title: Investigation of metallodrug/protein interaction by X-ray crystallography and complementary biophysical techniques Article Snippet: Protein metalation, the process by which a metal compound (or a metal ion) reacts with a protein to produce a metal/protein adduct, is at the basis of many biological events; the knowledge of this process at the atomic level is important in the design and development of new metallodrug-based therapeutic approaches.. Recently, single crystal X-ray diffraction experiments have been frequently used to characterize the structures of the adducts formed upon the reaction of Pt, Au, Ru, Rh, Ir, Cu, Mn and V-based drugs with proteins.. Although X-ray crystallography is certainly useful to determine the structure of these adducts, the combination with other biophysical techniques provides insights into the system behavior in solution, the reactivity of metal compounds with proteins, fate and stability of the metal/protein adduct and is often helpful for the rationalization of ambiguous or unexpected crystallographic data. |